This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Since its launch in April 2021, DeepIntent Outcomes has been used to automatically optimize media based on real-world clinical data for 85 leading pharmaceutical brands, with over 50 brands benefiting from DeepIntent Outcomes year to date. ” Marketing Technology News: MarTech Interview with Chris Knowlton, Chief Evangelist at Panopto.
Top Stories The Trade Desk’s Share Price Slides as Ad Demand Stutters Demandsideplatform The Trade Desk saw its share price fall by nearly 30 percent after the company said it’s seen a slowdown in ad demand on its platform in its Q3 earnings.
Various programmatic advertising platforms such as demand-sideplatforms (DSPs) utilize algorithms to adjust ad spending and targeting rapidly, making programmatic ad buying a perfect fit for AI applications. The platform aims to streamline content supply chains and enhance Pfizer’s marketing strategies.
Restrictions on pharmaceutical ads look likely, says Madison and Wall’s CEO, CFA and principal Brian Wieser. And this would hit TV particularly hard, since pharmaceutical companies invest heavily in TV. With visibility into over a billion video ad impressions daily, we see the sustainability issues that need fixing.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
84 
Let's personalize your content